glp 1 agonist for weight loss The New Management Meds The Buzz Around GLP-1 Agonists
Description
The introduction of an injectable GLP-1 has opened up new possibilities for patients with type 2 diabetes and obesity
February 2026: Zepbounds sales exceeded expectations by nearly $1 billion in the last quarter of 2025, according to Eli Lillys most recent earnings report
Figure 31: Photograph of Professor Bernard Thorens, credit Center for Integrative Genomics, University of Lausanne
Garza K, Aminpour E, Shah J, et al
One of the newest GLP-1s is called semaglutide
Phase II and III clinical trials are currently underway to evaluate its treatment potential and safety in MASH
